Replies to post #1580 on Biotech Values

[mskatiescarletohara]

“several key U.S. macular degeneration clinical trials” in 2004

Sounds agressive to me, it appears they want to enroll the trials in an expedient manner, I also believe it's imperative for GENR to do such if they wish to be competitive with the other ocular studies which are enrolling, one key advantage is MOA.

I would like to know what 'cost per patient' is involved with conducting such trials, and who the manufacturer is for Squalamine. I also believe GENR will have to secure a partnership to move forward at the pace they are implying in today's PR.

I'll be watching to see if Jason Kantor issues any comments on today's report.

katie....

[swampboots]

<Even with GENR’s strengthened balance sheet from recent financings, GENR does not on its own have the resources to conduct “several key U.S. macular degeneration clinical trials” in 2004, as indicated in Dr. Levitt’s quote. Hence, a reasonable inference is that GENR believes a partnership deal will get done relatively soon.>

There is a detective exception imaginable (in dream state). If unofficial follow-up of previous subjects shouted stunning persistent effectiveness, GENR will keep whole pie with stock dilutions

[EZ2]

music to my EarZ !!!!!!!!!!! 8-)